Open AccessEffects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: Insights from the EXSCEL trial
Author(s) -
L.E. Clegg,
R.C. Penland,
S. Bachina,
D.W. Boulton,
M. Thuresson,
H.J.L. Heerspink,
S. Gustavson,
C.D. Sjöström,
J.A. Ruggles,
A.F. Hernandez,
J.B. Buse,
R.J. Mentz,
R.R. Holman
Publication year - 2019
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/brjm-hg52
Subject(s) - exenatide , type 2 diabetes , medicine , open label , diabetes mellitus , clinical trial , intensive care medicine , endocrinology